SEC Filings

Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT^® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

Filing date	Form	Description	View
Aug 21, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-009220.pdf 0001179110-20-009220.rtf 0001179110-20-009220.xls
Aug 19, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-009172.pdf 0001179110-20-009172.rtf 0001179110-20-009172.xls
Jul 31, 2020	10-Q	Quarterly report which provides a continuing view of a company's financial position	View HTML 0001558370-20-008810.pdf 0001558370-20-008810.rtf 0001558370-20-008810.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Jul 31, 2020	424B5	Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3	View HTML 0001104659-20-089051.pdf 0001104659-20-089051.rtf 0001104659-20-089051.xls
Jul 30, 2020	8-K	Report of unscheduled material events or corporate event	View HTML 0001558370-20-008695.pdf 0001558370-20-008695.rtf 0001558370-20-008695.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Jul 24, 2020	8-K	Report of unscheduled material events or corporate event	View HTML 0001558370-20-008389.pdf 0001558370-20-008389.rtf 0001558370-20-008389.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Jul 14, 2020	8-K	Report of unscheduled material events or corporate event	View HTML 0001558370-20-008123.pdf 0001558370-20-008123.rtf 0001558370-20-008123.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Jul 08, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-008109.pdf 0001179110-20-008109.rtf 0001179110-20-008109.xls
Jul 06, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001104659-20-081384.pdf 0001104659-20-081384.rtf 0001104659-20-081384.xls
Jul 01, 2020	8-K	Report of unscheduled material events or corporate event	View HTML 0001558370-20-007910.pdf 0001558370-20-007910.rtf 0001558370-20-007910.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Investors & Media

Transformative science, targeted medicines

SEC Filings

Pagination